{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:00:51Z","timestamp":1791223251953,"version":"4.1.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2161,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1111\/j.1365-2133.2009.09246.x","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T11:30:52Z","timestamp":1240399852000},"page":"723-731","source":"Crossref","is-referenced-by-count":73,"title":["Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid"],"prefix":"10.1093","volume":"161","author":[{"given":"H.M.","family":"G\u00fcrcan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Razzaque Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0162-3109(00)00189-2","article-title":"Mechanisms of action of methotrexate","volume":"47","author":"Genestier","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1529-8019.2007.00135.x","article-title":"Methotrexate in dermatology","volume":"20","author":"Bangert","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0025-7125(05)70415-6","article-title":"The blistering diseases. Office dermatology, Part II","volume":"82","author":"Scott","year":"1998","journal-title":"Med Clin North Am"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archderm.1996.03890260105016","article-title":"The adjuvant therapy of pemphigus. An update","volume":"132","author":"Bystryn","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archderm.1971.04000140027005","article-title":"Studies in bullous diseases. Treatment of pemphigus vulgaris with immunosuppressives (steroids and methotrexate) and leucovorin calcium","volume":"103","author":"Peck","year":"1971","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/archderm.1969.01610250076018","article-title":"Treatment of pemphigus vulgaris with methotrexate","volume":"100","author":"Lever","year":"1969","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0091-6749(73)90062-6","article-title":"An approach to the use of immunosuppressive drugs in nonmalignant diseases","volume":"52","author":"Steinberg","year":"1973","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2133.1968.tb12317.x","article-title":"Methotrexate in dermatology","volume":"80","author":"Burrows","year":"1968","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1001\/archderm.1971.04000190016003","article-title":"Pemphigus. A 20-year survey of experience with 70 cases","volume":"104","author":"Ryan","year":"1971","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB10","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archderm.1984.01650430127024","article-title":"Adjuvant therapy of pemphigus","volume":"120","author":"Bystryn","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB11","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics","volume":"58","author":"Gottlieb","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2133.1970.tb15707.x","article-title":"Immunosuppressants in the treatment of pemphigus","volume":"83","author":"Jablonska","year":"1970","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB14","first-page":"171","article-title":"Pemphigus: combined treatment with methotrexate and prednisone","volume":"58","author":"Piamphongsant","year":"1975","journal-title":"J Med Assoc Thai"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB15","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/archderm.1977.01640090084013","article-title":"Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975","volume":"113","author":"Lever","year":"1977","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/archderm.1972.01620130023006","article-title":"Methotrexate and prednisone in pemphigus vulgaris. Therapeutic results obtained in 36 patients between 1961 and 1970","volume":"106","author":"Lever","year":"1972","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB17","first-page":"413","article-title":"Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin","volume":"68","author":"Mashkilleyson","year":"1988","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB18","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/archderm.135.10.1275","article-title":"Methotrexate as an adjuvant treatment for pemphigus vulgaris","volume":"135","author":"Smith","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-4362.1973.tb00016.x","article-title":"Use of methotrexate to treat pemphigus foliaceus","volume":"12","author":"Rivitti","year":"1973","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB20","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archderm.1978.01640230013003","article-title":"Bullous pemphigoid: therapy in patients with and without diabetes mellitus","volume":"114","author":"Downham","year":"1978","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB21","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0190-9622(94)70227-6","article-title":"Low-dose methotrexate treatment in elderly patients with bullous pemphigoid","volume":"31","author":"Paul","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0190-9622(99)70156-8","article-title":"Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid","volume":"40","author":"Heilborn","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB23","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/archderm.138.9.1255","article-title":"Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases","volume":"138","author":"Dereure","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB24","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/archderm.139.11.1506-b","article-title":"Methotrexate for bullous pemphigoid: preliminary study","volume":"139","author":"Bara","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB25","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ophtha.2003.07.010","article-title":"Methotrexate therapy for ocular cicatricial pemphigoid","volume":"111","author":"McCluskey","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/archderm.144.5.612","article-title":"A retrospective analysis of patients with bullous pemphigoid treated with methotrexate","volume":"144","author":"Kjellman","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2133.1985.tb02079.x","article-title":"Evidence of an association between bullous pemphigoid and psoriasis","volume":"113","author":"Grattan","year":"1985","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2133.1976.tb00865.x","article-title":"Bullous pemphigoid and psoriasis: does subclinical bullous pemphigoid exist?","volume":"95","author":"Person","year":"1976","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB29","first-page":"134","article-title":"[Psoriasis and bullous dermatoses]","volume":"29","author":"St\u00fcttgen","year":"1978","journal-title":"Hautarzt"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB30","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1001\/archderm.1978.01640230017005","article-title":"Coexistent psoriasis and bullous pemphigoid: a report of six cases","volume":"114","author":"Koerber","year":"1978","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB31","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002512-200825080-00001","article-title":"Role of methotrexate in the treatment of bullous pemphigoid in the elderly","volume":"25","author":"Patton","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.57.2.3","article-title":"Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis","volume":"57","author":"Cronstein","year":"2005","journal-title":"Pharmacol Rev"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB33","first-page":"168","article-title":"Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis","volume":"65","author":"Tian","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB34","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2165\/00002512-200320100-00002","article-title":"Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives?","volume":"20","author":"Drosos","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.clim.2004.03.010","article-title":"Immunosuppressants, infection, and inflammation","volume":"113","author":"Lovell","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB36","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/rheumatology\/kei031","article-title":"A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal","volume":"44","author":"Choy","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB37","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0190-9622(98)70508-0","article-title":"Methotrexate in psoriasis: consensus conference","volume":"38","author":"Roenigk","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB38","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1191\/096120301666080831","article-title":"Methotrexate therapy in systemic lupus erythematosus","volume":"10","author":"Sato","year":"2001","journal-title":"Lupus"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB39","first-page":"CD003208","article-title":"Methotrexate for multiple sclerosis","volume":"2","author":"Gray","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB40","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3748\/wjg.14.354","article-title":"Treatment of inflammatory bowel disease: a review of medical therapy","volume":"14","author":"Kozuch","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cld.2007.11.011","article-title":"Role of methotrexate in the treatment of chronic cholestatic disorders","volume":"12","author":"Novak","year":"2008","journal-title":"Clin Liver Dis"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00128071-200809020-00001","article-title":"Clinical approach to cutaneous vasculitis","volume":"9","author":"Chen","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/BOR.0b013e3282f31769","article-title":"Improving therapeutic options for patients with giant cell arteritis","volume":"20","author":"Pipitone","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB44","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/BOR.0b013e3282f13137","article-title":"Current drug therapy for scleroderma and secondary Raynaud\u2019s phenomenon: evidence-based review","volume":"19","author":"Henness","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/jnnp.2007.124263","article-title":"Sarcoidosis of the nervous system","volume":"7","author":"Joseph","year":"2007","journal-title":"Pract Neurol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB46","first-page":"453","article-title":"The therapy of Sj\u00f6gren\u2019s syndrome: a review","volume":"158","author":"Coaccioli","year":"2007","journal-title":"Clin Ter"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB47","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1742-1241.2007.01295.x","article-title":"Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches","volume":"61","author":"Gong","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB48","first-page":"1125","article-title":"Update on the treatment of ankylosing spondylitis","volume":"3","author":"Maksymowych","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB49","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/sj.bmt.1705922","article-title":"Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children","volume":"41","author":"Inagaki","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB50","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1080\/03009740510018570","article-title":"Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register from 1991 to 1999","volume":"34","author":"Kuitunen","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB51","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB52","unstructured":"52National Patient Safety Agency. Improving compliance with oral methotrexate guidelines. NPSA Patient Safety Alert, June 2006. Available at: http:\/\/www.npsa.nhs.uk\/EasySiteWeb\/GatewayLink.aspx?alId=1494 (last accessed 7 May 2009)."},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB53","unstructured":"53British Association of Dermatologists. Methotrexate. Available at: http:\/\/www.bad.org.uk\/site\/1121\/default.aspx (last accessed 7 May 2009)."},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB54","first-page":"CD000951","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"2","author":"Ortiz","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB55","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1365-2133.2007.08426.x","article-title":"Methotrexate: prescribing and monitoring practices among the consultant membership of the British Association of Dermatologists","volume":"158","author":"Collin","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB56","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2133.2005.06459.x","article-title":"Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen","volume":"152","author":"Maurice","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB57","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2133.2005.06422.x","article-title":"Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis","volume":"152","author":"Chalmers","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB58","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2133.2001.03959.x","article-title":"The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up","volume":"144","author":"Zachariae","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB59","first-page":"1586","article-title":"Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines?","volume":"29","author":"Yazici","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB60","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1002\/art.11277","article-title":"Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events","volume":"48","author":"Yazici","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2009.09246.x-BIB61","first-page":"517","article-title":"Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities","volume":"23","author":"Yazici","year":"2005","journal-title":"Clin Exp Rheumatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2009.09246.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2009.09246.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:45:35Z","timestamp":1676382335000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/161\/4\/723\/6642136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09246.x","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}